SCHEMBL23980883

SCHEMBL23980883

CC(C)(C)OC(=O)N1CCC(c2cccc3c2CCNC3)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
NAMPT P43490 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
KDM1A O60341 2/20 0.46
GPR119 Q8TDV5 4/20 0.44
MAPK1 P28482 1/20 0.43
RBP4 P02753 2/20 0.42
STS P08842 1/20 0.41
HPGDS O60760 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25427744 0.94 DDB1 (0.48) DDB1CRBNNAMPTKDM4EMAPT
SCHEMBL14591408 0.91 DDB1 (0.47) DDB1CRBNNAMPTKDM4EMAPT
SCHEMBL23780200 0.86 NAMPT (0.52) DDB1CRBNNAMPTKDM4EMAPT
SCHEMBL25426004 0.85 DDB1 (0.48) DDB1CRBNNAMPTKDM4EMAPT
SCHEMBL26100307 0.82 MAPK1 (0.50) DDB1CRBNNAMPTKDM4EMAPT
SCHEMBL28901610 0.82 KDM4E (0.45) DDB1CRBNNAMPTKDM4EKDM1A
SCHEMBL29554785 0.82 KDM4E (0.45) DDB1CRBNNAMPTKDM4EKDM1A
SCHEMBL5202938 0.81 MAPK1 (0.46) DDB1CRBNNAMPTMAPTKDM1A
SCHEMBL21326156 0.78 DDB1 (0.56) DDB1CRBNNAMPTMAPTTHRB
SCHEMBL22978632 0.78 RBP4 (0.42) MAPTRBP4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR DDB1 4794/4885CRBN 4866/4885NAMPT 2068/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R DDB1 3999/4885CRBN 2580/4885NAMPT 4698/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR DDB1 4794/4885CRBN 4866/4885NAMPT 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.